Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | EVOLVE: Orva-cel in RRMM

Sham Mailankody • 27 May 2020
ASCO 2020
Multiple Myeloma Orvacabtagene autoleucel
EVOLVE

Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, discusses data from the EVOLVE phase 1/2 study (NCT03430011) of orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy, in patients with relapsed/refratory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sham Mailankody

Updates in multiple myeloma
Nizar Bahlis et al. • 14 Apr 2023
2:39
What are the next steps for CAR-T in myeloma?
Sham Mailankody • 8 Dec 2020
5:31
Emerging immunotherapies for myeloma
Sham Mailankody • 8 Dec 2020
4:02
ALLO-715: BCMA allogeneic CAR-T in R/R myeloma
Sham Mailankody • 8 Dec 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals